Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.063|
|52 Week High||AU$0.061|
|52 Week Low||AU$0.19|
|1 Month Change||-7.35%|
|3 Month Change||-18.18%|
|1 Year Change||-40.00%|
|3 Year Change||-21.25%|
|5 Year Change||46.51%|
|Change since IPO||110.00%|
Recent News & Updates
We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Botanix Pharmaceuticals...
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|BOT||AU Pharmaceuticals||AU Market|
Return vs Industry: BOT underperformed the Australian Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: BOT underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: BOT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BOT's weekly volatility (6%) has been stable over the past year.
About the Company
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. Its product pipeline include BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase Ib clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in North Perth, Australia.
Botanix Pharmaceuticals Fundamentals Summary
|BOT fundamental statistics|
Is BOT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BOT income statement (TTM)|
|Cost of Revenue||AU$6.57m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0034|
|Net Profit Margin||-48.41%|
How did BOT perform over the long term?See historical performance and comparison
Is Botanix Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BOT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BOT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BOT is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: BOT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BOT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BOT is good value based on its PB Ratio (2.9x) compared to the AU Pharmaceuticals industry average (3.7x).
How is Botanix Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Botanix Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Botanix Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOT is currently unprofitable.
Growing Profit Margin: BOT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BOT is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare BOT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: BOT has a negative Return on Equity (-16.03%), as it is currently unprofitable.
How is Botanix Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BOT's short term assets (A$21.6M) exceed its short term liabilities (A$1.0M).
Long Term Liabilities: BOT's short term assets (A$21.6M) exceed its long term liabilities (A$112.2K).
Debt to Equity History and Analysis
Debt Level: BOT is debt free.
Reducing Debt: BOT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BOT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BOT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.5% each year
What is Botanix Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BOT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BOT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BOT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vince Ippolito (62 yo)
Mr. Vincent P. Ippolito, also known as Vince, serves as the President of Botanix Pharmaceuticals Limited since May 20, 2019 and Executive Chairman since July 18, 2019. Mr. Ippolito is Acting Managing Direc...
CEO Compensation Analysis
Compensation vs Market: Vince's total compensation ($USD754.49K) is above average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Vince's compensation has been consistent with company performance over the past year.
Experienced Management: BOT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: BOT's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Botanix Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Botanix Pharmaceuticals Limited
- Ticker: BOT
- Exchange: ASX
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$61.308m
- Shares outstanding: 973.14m
- Website: https://www.botanixpharma.com
Number of Employees
- Botanix Pharmaceuticals Limited
- 50 Angove Street
- Level 1
- North Perth
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:29|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.